Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Viral respiratory tract infections diagnosis: a Spanish survey and consensus approach.

Diagnostic microbiology and infectious disease·2025
Same author

Ventricular Access Utilizing Cutaneous Reference Points: Statistical Analysis and Proposal of a New Ventricular Entry Point.

World neurosurgery·2024
Same author

Eosinophilic fasciitis following SARS-CoV-2 vaccination.

JAAD case reports·2023
Same author

Bacterial Patterns and Empiric Antibiotic Use in COPD Patients With Community-Acquired Pneumonia.

Archivos de bronconeumologia·2022
Same author

Acute Myocardial Injury During SARS-CoV-2 Pneumonia and Long-term Prognosis.

Journal of general internal medicine·2022
Same author

Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia.

Chest·2020
Same journal

Advances in Sarcoidosis.

Archivos de bronconeumologia·2026
Same journal

Spanish Clinical Practice Guidelines for the Diagnosis and Management of Alpha-1 Antitrypsin Deficiency: 2026 Update.

Archivos de bronconeumologia·2026
Same journal

Thoracic Sympathectomy for Harlequin Syndrome.

Archivos de bronconeumologia·2026
Same journal

Prognostic Significance of Electrocardiographic Findings in Hemodynamically Stable Patients With Acute Pulmonary Embolism: Insights From the RIETE Registry.

Archivos de bronconeumologia·2026
Same journal

Endothelial and Angiogenic Biomarkers in Obstructive Sleep Apnea: Longitudinal Associations With Continuous Positive Airway Pressure.

Archivos de bronconeumologia·2026
Same journal

Robotic Resection of Ectopic Paratracheal Thymoma: A Case Report.

Archivos de bronconeumologia·2026
See all related articles

Related Experiment Video

Updated: Jun 4, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

[Community-acquired pneumonia].

José Blanquer1, Francisco Sanz

  • 1Unidad Cuidados Intensivos Respiratorios, Hospital Clínic Universitari, Valencia, España. blanquer_jos@gva.es

Archivos De Bronconeumologia
|February 15, 2011
PubMed
Summary
This summary is machine-generated.

Determining the cause of community-acquired pneumonia (CAP) is challenging. Severity assessment is crucial for stratifying patients and guiding treatment, with Streptococcus pneumoniae a common cause across all severity groups.

More Related Videos

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Related Experiment Videos

Last Updated: Jun 4, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Experimental Model to Evaluate Resolution of Pneumonia
09:49

Experimental Model to Evaluate Resolution of Pneumonia

Published on: February 17, 2023

Area of Science:

  • Medical Microbiology
  • Pulmonology
  • Infectious Diseases

Context:

  • Community-acquired pneumonia (CAP) diagnosis is often etiological challenging, with only 40-60% of cases identified.
  • Accurate severity assessment is vital for emergency department patient stratification.
  • Stratification guides decisions on outpatient care, hospitalization, or intensive care unit (ICU) admission.

Purpose:

  • To highlight the importance of severity assessment in managing CAP patients.
  • To outline key severity scales (PSI, CURB-65, ATS-IDSA 2007) for CAP management.
  • To emphasize tailored etiological testing and antibiotic strategies based on patient stratification.

Summary:

  • Severity assessment, using tools like PSI and CURB-65, is critical for CAP patient management.
  • Distinct etiological investigations and empirical antibiotic treatments are necessary for different patient strata.
  • Streptococcus pneumoniae is a prevalent cause of CAP across all severity levels, requiring consideration in empirical treatment.

Impact:

  • Improved patient stratification leads to more appropriate resource allocation in healthcare settings.
  • Tailored diagnostic and therapeutic approaches enhance CAP management outcomes.
  • Recognition of common etiologies like Streptococcus pneumoniae informs empirical antibiotic selection and public health strategies.